Preços dos medicamentos vão "inevitavelmente" subir, avisam as farmacêuticas

[Keyser Soze]

ImClone Systems rose $2.23 pre-market, or 8.2 percent, to $29.40. The biotechnology company was offered $36 a share last month from a "major international pharmaceutical company,'' it said in a document it planned to file with securities regulators. The offer was rejected after billionaire investor Carl Icahn refused to support it, ImClone said.